ALINT.PA Integragen

Healthcare Biotechnology Euronext Paris
0.0752 EUR
Close of Oct 31, 2026
0.0130 0.3610
Market cap
EUR 497K
P/E
-
P/B
0.58x
ROE
-
Dividend yield
-
Fundamental score
0.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALINT.PA undervalued?

Graham number

The Graham number of Integragen cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Integragen fundamental analysis

1 of 11 checks passed

ROE 0/2

Negative ROE (-0.16%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-0.04%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 0/2

The stock's elevated P/BV ratio (3.04x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

DER 1/2

The stock maintains a fair debt to equity ratio (77%), indicating a reasonable balance between the money it owes and the ownership it possesses.

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Graham Number 0/1

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

Dividend Growth 0/2

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Dividend 0/2

The company's lack of dividends in the past three years may concern investors seeking regular income.

Buffet Intrinsic Value 0/1

Warren Buffett's formula suggests that the company's stock is overpriced (-1.900), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Integragen stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Integragen

IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing …

Full company profile